Design and synthesis of potent beta-secretase (BACE1) inhibitors with P1' carboxylic acid bioisosteres

Bioorg Med Chem Lett. 2006 May 1;16(9):2380-6. doi: 10.1016/j.bmcl.2006.01.108. Epub 2006 Feb 14.

Abstract

Recently, we reported potent and small-sized beta-secretase (BACE1) inhibitors KMI-420 and KMI-429 in which we replaced the Glu residue at the P4 position of KMI-260 and KMI-360, respectively, with a 1H-tetrazole-5-carbonyl DAP (L-alpha,beta-diaminopropionic acid) residue. At the P1' position, these compounds contain one or two carboxylic acid groups, which are unfavorable for crossing the blood-brain barrier. Herein, we report BACE1 inhibitors with P1' carboxylic acid bioisosteres in order to develop practical anti-Alzheimer's disease drugs. Among them, tetrazole ring-containing compounds, KMI-570 (IC50=4.8 nM) and KMI-684 (IC50=1.2 nM), exhibited significantly potent BACE1 inhibitory activities.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / drug therapy
  • Amyloid Precursor Protein Secretases
  • Carboxylic Acids / chemistry*
  • Crystallography, X-Ray
  • Drug Design*
  • Drug Evaluation, Preclinical
  • Endopeptidases / drug effects*
  • Enzyme Inhibitors / chemical synthesis*
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology
  • Models, Molecular
  • Molecular Structure
  • Oligopeptides / chemical synthesis*
  • Oligopeptides / chemistry
  • Oligopeptides / pharmacology
  • Stereoisomerism
  • Structure-Activity Relationship

Substances

  • Carboxylic Acids
  • Enzyme Inhibitors
  • KMI-420
  • KMI-429
  • Oligopeptides
  • Amyloid Precursor Protein Secretases
  • Endopeptidases